Selective Targeting of RET Fusions in Lung Cancer

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. September 19, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.01644 Journal of Clinical Oncology - published online before print September 19, 2022 PMID: 36122320 Selective Targeting of RET Fusions in Lung Cancer Jessica J. Lin , MD1xJessica J. LinSearch for articles by this author and Justin F. Gainor , MD1xJustin F. GainorSearch for articles by this author Show More 1Department of Medicine, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Boston, MA https://doi.org/10.1200/JCO.22.01644 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsFinancial support: Justin F. GainorAdministrative support: Justin F. GainorCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTSelective Targeting of RET Fusions in Lung CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jessica J. LinHonoraria: Pfizer, OncLiveConsulting or Advisory Role: C4 Therapeutics, Genentech, Nuvalent Inc, Blueprint Medicines, Turning Point Therapeutics, Bayer, Mirati Therapeutics, Novartis, Elevation OncologyResearch Funding: Hengrui Therapeutics (Inst), Turning Point Therapeutics (Inst), Novartis (Inst), Neon Therapeutics (Inst), Relay Therapeutics (Inst), Elevation Oncology (Inst), Bayer (Inst), Roche (Inst), Linnaeus Therapeutics (Inst), Nuvalent Inc (Inst)Travel, Accommodations, Expenses: PfizerJustin F. GainorThis author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: Ironwood PharmaceuticalsStock and Other Ownership Interests: Ironwood PharmaceuticalsHonoraria: Merck, Novartis, Pfizer, Takeda, BeiGeneConsulting or Advisory Role: Genentech, Bristol Myers Squibb, Takeda, Amgen, Merck, Jounce Therapeutics, Blueprint Medicines, Gilead Sciences, Lilly, Moderna Therapeutics, Karyopharm Therapeutics, ITeos Therapeutics, Pfizer, Mirati Therapeutics, Nuvalent Inc, EMD Serono, Silverback Therapeutics, Novartis, BeiGeneResearch Funding: Merck (Inst), Novartis (Inst), Genentech, Bristol Myers Squibb (Inst), Adaptimmune (Inst), AstraZeneca (Inst), Jounce Therapeutics (Inst), Blueprint Medicines (Inst), Moderna Therapeutics (Inst), Tesaro (Inst), Alexo Therapeutics (Inst)Open Payments Link: https://openpaymentsdata.cms.gov/physician/775917No other potential conflicts of interest were reported. Companion Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial